PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-22.17%
R&D reduction while AGEN shows 23.59% growth. Joel Greenblatt would examine competitive risk.
-22.47%
G&A reduction while AGEN shows 21.53% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
-12.79%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-22.23%
Operating expenses reduction while AGEN shows 21.53% growth. Joel Greenblatt would examine advantage.
-22.23%
Total costs reduction while AGEN shows 23.10% growth. Joel Greenblatt would examine advantage.
10981.63%
Interest expense growth above 1.5x AGEN's 8.47%. Michael Burry would check for over-leverage.
-12.79%
Both companies reducing D&A. Martin Whitman would check industry patterns.
22.24%
EBITDA growth exceeding 1.5x AGEN's 7.00%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
22.23%
Operating income growth exceeding 1.5x AGEN's 5.28%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
-88.23%
Other expenses reduction while AGEN shows 2.59% growth. Joel Greenblatt would examine advantage.
18.34%
Pre-tax income growth exceeding 1.5x AGEN's 4.90%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
88.23%
Tax expense growth while AGEN reduces burden. John Neff would investigate differences.
18.34%
Net income growth exceeding 1.5x AGEN's 4.90%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
32.95%
EPS growth exceeding 1.5x AGEN's 5.96%. David Dodd would verify competitive advantages.
32.95%
Diluted EPS growth exceeding 1.5x AGEN's 5.96%. David Dodd would verify competitive advantages.
21.91%
Share count reduction below 50% of AGEN's 1.07%. Michael Burry would check for concerns.
21.91%
Diluted share reduction below 50% of AGEN's 1.07%. Michael Burry would check for concerns.